STOCK TITAN
  1. Home
  2. News
  3. IMGN

ImmunoGen, Inc. - IMGN STOCK NEWS

Welcome to our dedicated page for ImmunoGen news (Ticker: IMGN), a resource for investors and traders seeking the latest updates and insights on ImmunoGen stock.

ImmunoGen, Inc. (NASDAQ: IMGN) is a pioneering clinical-stage biotechnology company focused on developing targeted anticancer therapeutics using proprietary antibody-drug conjugate (ADC) technology. The company's mission is to create groundbreaking treatments that improve outcomes for cancer patients.

ImmunoGen's flagship product, ELAHERE® (mirvetuximab soravtansine-gynx), is a first-in-class ADC that has received accelerated approval from the U.S. FDA for treating adult patients with folate receptor alpha (FRα) positive, platinum-resistant ovarian cancer. This innovative therapy is the first targeted medicine to demonstrate a meaningful survival benefit in this patient group.

Recent News: On November 30, 2023, AbbVie Inc. (NYSE: ABBV) and ImmunoGen announced a definitive agreement under which AbbVie will acquire ImmunoGen for $31.26 per share in cash. This acquisition, valued at approximately $10.1 billion, is expected to close in mid-2024, pending shareholder and regulatory approvals.

ImmunoGen has a robust pipeline of next-generation ADCs, including IMGN-151, designed for ovarian cancer, and Pivekimab sunirine, targeting rare blood cancer BPDCN. The company's technology is also utilized in Roche's marketed product, Kadcyla, highlighting its industry-wide impact.

With its innovative approaches and strategic partnerships, ImmunoGen is at the forefront of developing cutting-edge cancer therapies aimed at disrupting the progression of cancer and offering patients more good days.

  • Lead Product: ELAHERE® for platinum-resistant ovarian cancer
  • Pipeline Products: IMGN-151, Pivekimab sunirine
  • Partnerships: Roche, AbbVie
  • Technology: Proprietary antibody-drug conjugate (ADC) technology
  • Financial Condition: Recently valued at $10.1 billion in acquisition deal with AbbVie
  • Website: www.immunogen.com
News

Seaport Therapeutics Names Lauren White as Chief Financial Officer

Rhea-AI Summary

Lauren White has been appointed as Chief Financial Officer of Seaport Therapeutics, a clinical-stage biopharmaceutical company focused on neuropsychiatric medicines. White previously served as CFO at ImmunoGen, where she played a important role in the company's $10.1 billion acquisition by AbbVie in 2024 and the commercial launch of ELAHERE®. With over 22 years of experience, White's background includes positions at C4 Therapeutics, Novartis, Boston Consulting Group, and General Electric. She holds a BS from Boston College and an MBA from Harvard Business School.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
none
-
News

AbbVie Completes Acquisition of ImmunoGen

Rhea-AI Summary
AbbVie completes acquisition of ImmunoGen, adding ELAHERE, a transformative treatment for ovarian cancer, to its portfolio. The acquisition expands AbbVie's oncology pipeline, reaffirms 2024 EPS guidance, and positions the company for long-term growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
acquisition
-
News

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
ImmunoGen, Inc. announced the approval of the grant of restricted stock units (RSUs) to eleven new employees under the Inducement Plan, covering 68,940 shares of ImmunoGen’s common stock. The RSUs will vest over a period of four years, subject to the employee’s continued employment on each vesting date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
none
News

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
ImmunoGen, Inc. (Nasdaq: IMGN) announces the grant of restricted stock units (RSUs) covering 167,159 shares of ImmunoGen’s common stock under the Inducement Equity Incentive Plan to six new employees. Each RSU will vest as to 25% of the shares on the first anniversary of the grant date and as to an additional 25% annually thereafter for the next three years, subject to the employee’s continued employment on each vesting date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
none
-
News

ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

Rhea-AI Summary
ImmunoGen Inc. (IMGN) announces encouraging safety and efficacy results from pivekimab triplet combination for newly diagnosed acute myeloid leukemia (AML) at the 65th American Society of Hematology (ASH) Annual Meeting. The pivekimab triplet demonstrates high complete remission (CR), composite CR, and minimal residual disease (MRD) negativity rates, supporting continued development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer

Rhea-AI Summary
ImmunoGen, Inc. (IMGN) has been granted Priority Review by the FDA for the conversion of the accelerated approval of ELAHERE for the treatment of patients with FRα-positive, platinum-resistant ovarian cancer to full approval, with a PDUFA action date of April 5, 2024. The confirmatory Phase 3 MIRASOL trial demonstrated statistically significant and clinically meaningful improvements in progression-free survival, objective response rate, and overall survival compared to single-agent chemotherapy, with a tolerable safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
none
News

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
ImmunoGen, Inc. (IMGN) announced the grant of 112,252 restricted stock units to twelve new employees under the Inducement Plan. Each RSU will vest annually, subject to the employee's continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
none
-
News

AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio

Rhea-AI Summary
AbbVie Inc. (NYSE: ABBV) is set to acquire ImmunoGen, Inc. (NASDAQ: IMGN) for $10.1 billion, accelerating its entry into the commercial market for ovarian cancer with the first-in-class antibody-drug conjugate (ADC) ELAHERE®. The transaction, valued at $31.26 per share, aims to diversify AbbVie's oncology pipeline across solid tumors and hematologic malignancies, with potential transformative impact on long-term revenue growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.81%
Tags
acquisition
-
News

ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies London Healthcare Conference

Rhea-AI Summary
ImmunoGen, Inc. (Nasdaq: IMGN) will participate in a fireside chat at the Jefferies London Healthcare Conference on November 15, 2023. The webcast will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.1%
Tags
none
News

ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results

Rhea-AI Summary
ImmunoGen Inc. reported strong Q3 results with net sales of $105.2 million for ELAHERE. The company achieved key milestones including acceptance of MAA by EMA and NDA by NMPA for ELAHERE. They also announced a collaboration with Takeda to develop and commercialize ELAHERE in Japan. The PICCOLO trial of ELAHERE in platinum-sensitive ovarian cancer met its primary endpoint. ImmunoGen also made progress in their other programs and expanded their leadership team.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.75%
Tags
earnings

FAQ

What is the market cap of ImmunoGen (IMGN)?

The market cap of ImmunoGen (IMGN) is approximately 8.7B.

What does ImmunoGen, Inc. specialize in?

ImmunoGen, Inc. specializes in developing targeted anticancer therapeutics using proprietary antibody-drug conjugate (ADC) technology.

What is ELAHERE®?

ELAHERE® (mirvetuximab soravtansine-gynx) is ImmunoGen's lead product, a first-in-class ADC approved for treating FRα positive, platinum-resistant ovarian cancer.

Who is acquiring ImmunoGen, Inc.?

AbbVie Inc. is acquiring ImmunoGen, Inc. in a deal valued at approximately $10.1 billion.

What is the significance of the acquisition by AbbVie?

The acquisition expands AbbVie's oncology portfolio with ImmunoGen's innovative ADC technology and products, accelerating its presence in the solid tumor space.

What other products are in ImmunoGen's pipeline?

ImmunoGen's pipeline includes IMGN-151 for ovarian cancer and Pivekimab sunirine targeting BPDCN, a rare blood cancer.

What technology does ImmunoGen use?

ImmunoGen uses proprietary antibody-drug conjugate (ADC) technology to create targeted cancer therapies.

What is Kadcyla?

Kadcyla is a marketed product by Roche that utilizes ImmunoGen's ADC technology for cancer treatment.

When is the acquisition by AbbVie expected to close?

The acquisition is expected to close in mid-2024, subject to shareholder and regulatory approvals.

Where can I find more information about ImmunoGen, Inc.?

More information can be found on ImmunoGen's official website at www.immunogen.com.

What is the focus of ImmunoGen's research and development?

ImmunoGen focuses on developing next-generation ADCs to improve cancer treatment outcomes by generating therapies with enhanced anti-tumor activity and favorable tolerability profiles.

Stock IMGN logo
ImmunoGen, Inc.

Nasdaq:IMGN

IMGN Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

IMGN Stock Data

8.72B
278.38M
0.32%
86.52%
7.38%
Biotechnology
Healthcare
Link
United States
Waltham